Ahmad Al-Mrabeh
Overview
Explore the profile of Ahmad Al-Mrabeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melhem S, Steven S, Taylor R, Al-Mrabeh A
Nutrients
. 2021 Apr;
13(5).
PMID: 33925808
Cardiovascular disease (CVD) remains a major problem for people with type 2 diabetes (T2DM), and the leading cause of death worldwide. We aimed to determine cardiovascular benefits of weight loss...
2.
Al-Mrabeh A, Peters C, Hollingsworth K, Taylor R
STAR Protoc
. 2021 Mar;
2(1):100355.
PMID: 33733239
Liver fat content and the linked rate of export of triglyceride are central to the etiology of type 2 diabetes, as well as to the cardiovascular effects of fatty liver...
3.
Al-Mrabeh A
Biomedicines
. 2021 Mar;
9(2).
PMID: 33672162
Cardiovascular disease (CVD) remains a major problem for people with type 2 diabetes mellitus (T2DM), and dyslipidemia is one of the main drivers for both metabolic diseases. In this review,...
4.
Thom G, McIntosh A, Messow C, Leslie W, Barnes A, Brosnahan N, et al.
Diabetes Obes Metab
. 2020 Dec;
23(3):711-719.
PMID: 33289256
Aim: To investigate whether appetite-related hormones were predictors of weight regain in the Diabetes Remission Clinical Trial (DiRECT). Materials And Methods: DiRECT is a cluster-randomized clinical trial, designed to assess...
5.
Al-Mrabeh A
Cardiovasc Endocrinol Metab
. 2020 Nov;
9(4):132-142.
PMID: 33225228
Type 2 diabetes has been regarded a complex multifactorial disease that lead to serious health complications including high cardiovascular risks. The twin cycle hypothesis postulated that both hepatic insulin resistance...
6.
Al-Mrabeh A, Hollingsworth K, Shaw J, McConnachie A, Sattar N, Lean M, et al.
Lancet Diabetes Endocrinol
. 2020 Oct;
8(12):939-948.
PMID: 33031736
Background: The pancreas is small and irregular in shape in people with type 2 diabetes. If these abnormalities are caused by the disease state itself rather than being a predisposing...
7.
Zhyzhneuskaya S, Al-Mrabeh A, Peters C, Barnes A, Aribisala B, Hollingsworth K, et al.
Diabetes Care
. 2020 Feb;
43(4):813-820.
PMID: 32060017
Objective: To assess functional β-cell capacity in type 2 diabetes during 2 years of remission induced by dietary weight loss. Research Design And Methods: A Stepped Insulin Secretion Test with...
8.
Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes A, Melhem S, Jesuthasan A, et al.
Cell Metab
. 2019 Dec;
31(2):233-249.e4.
PMID: 31866441
The role of hepatic lipoprotein metabolism in diet-induced remission of type 2 diabetes is currently unclear. Here, we determined the contributions of hepatic VLDL1-triglyceride production rate and VLDL1-palmitic acid content...
9.
Taylor R, Al-Mrabeh A, Sattar N
Lancet Diabetes Endocrinol
. 2019 May;
7(9):726-736.
PMID: 31097391
Clinical and pathophysiological studies have shown type 2 diabetes to be a condition mainly caused by excess, yet reversible, fat accumulation in the liver and pancreas. Within the liver, excess...
10.
Lean M, Leslie W, Barnes A, Brosnahan N, Thom G, McCombie L, et al.
Lancet Diabetes Endocrinol
. 2019 Mar;
7(5):344-355.
PMID: 30852132
Background: The DiRECT trial assessed remission of type 2 diabetes during a primary care-led weight-management programme. At 1 year, 68 (46%) of 149 intervention participants were in remission and 36...